European device experts return from break to heavy agenda
This article was originally published in Clinica
A number of crucial issues concerning high-risk medical devices will be on the European agenda as regulators return to work after their summer holidays. Judging from the welter of points raised at the July meeting of the European medical devices expert group, their next session scheduled for September 6 and 7, will be equally hectic.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.